title: [Transgenics - Plant-Based Drugs (PBD)].
abstract: Plant-Based Drugs - PBD - represent the 4(th) generation of genetically-modified plants and in this case the technology is used to develop and produce pharmaceuticals vaccines and/or products from transgenic seeds. This technology, like all scientific innovations, has inherent risks. However, the current knowledge available about the use of this technology means that no firm conclusions can be drawn about the nature of the risks involved, as well as their significance and the likelihood of causing serious damage or not. Risk analysis should be the starting premise prior to any implementation of techno-scientific innovations. The parameters must be evaluated and precautions taken and research must be conducted in a detailed and broad-ranging manner with respect to the potential risks of any innovation. This article analyzed the applicability of this new technology, as well as risk management and containment in order to guarantee safe use, handling and consumption by human beings.
authors.affiliation: Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. danielerachidi@yahoo.com.br
authors.forename: Daniele Rachidi da
authors.initials: DR
authors.lastname: Rocha
authors.forename: Victor Augustus
authors.initials: VA
authors.lastname: Marin
mesh_terms: D001938:Brazil; D004345:Drug Industry; D005818:Genetic Engineering / Q000331:legislation & jurisprudence; D030821:Plants, Genetically Modified / Q000378:metabolism; D011994:Recombinant Proteins / Q000096:biosynthesis; D012308:Risk Management
chemical_list: D011994:Recombinant Proteins